Patents by Inventor Takaichi Shimozato

Takaichi Shimozato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230212306
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Application
    Filed: December 27, 2022
    Publication date: July 6, 2023
    Applicants: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • Patent number: 11578138
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: February 14, 2023
    Assignees: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • Publication number: 20210332149
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 28, 2021
    Applicants: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • Patent number: 11091560
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: August 17, 2021
    Assignees: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • Publication number: 20210040225
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Application
    Filed: October 13, 2020
    Publication date: February 11, 2021
    Applicants: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • Patent number: 8101650
    Abstract: A method for treating an immunology-related disease. The method involves administering to a mammal in need thereof a pharmaceutically effective amount of an amino acid compound, a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof. The compound has the following formula: wherein R1 and R2 are each hydrogen; R3 is hydrogen; R4 is C1-C2 alkyl; n is 2; X is ?N-D, wherein D is hydrogen, C1-C4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH2 or phenylene; Z is ethylene or trimethylene; R5 is unsubstituted C3-C10 cycloalkyl, unsubstituted C3-C10 aryl, or C3-C10 cycloalkyl or C6-C10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R6 and R7 are each hydrogen.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: January 24, 2012
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Takahide Nishi, Takaichi Shimozato, Futoshi Nara, Shojiro Miyazaki
  • Patent number: 8067396
    Abstract: A compound having a formula II(a): wherein R1 and R2 are hydrogen lower alkyl, lower aliphatic acyl, or lower alkoxycarbonyl; R4 is C1-C4 alkyl; n is 2 or 3; X is a formula ?N-D, wherein D is hydrogen, C1-C6 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH2—, —CH(OH)—CH2— or phenylene; Z is C1-C6 alkylene; R5 is C3-C10 cycloalkyl or C6-C10 aryl; R6 and R7 are hydrogen, lower alkyl, halogeno lower alkyl, lower alkoxy or lower alkylthio; and R10 and R11 are hydrogen or lower alkyl.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: November 29, 2011
    Assignee: Sankyo Company, Limited
    Inventors: Takahide Nishi, Takaichi Shimozato, Futoshi Nara, Shojiro Miyazaki
  • Patent number: 7910617
    Abstract: A method for suppressing the number of peripheral blood lymphocytes involving administering to a human in need thereof a pharmaceutically effective amount of a compound which is (2R) -2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol or a pharmacologically acceptable salt thereof, such as the hydrochloride salt.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: March 22, 2011
    Assignee: Sankyo Company, Limited
    Inventors: Takahide Nishi, Toshiyasu Takemoto, Shojiro Miyazaki, Takaichi Shimozato, Futoshi Nara, Takashi Izumi
  • Publication number: 20100081702
    Abstract: Object The present invention provides a pharmaceutical composition for prophylaxis or treatment of hepatitis. Solution A pharmaceutical composition for prophylaxis or treatment of hepatitis, comprising a compound represented by the general formula (I): wherein R1 represents a C1-C4 alkyl group, R2 and R3 which are the same or different represent a hydrogen atom, a C1-C4 alkyl group, or a C1-C4 alkoxy group, X represents a sulfur atom or a nitrogen atom substituted by a methyl group, and n represents an integer of 3 or 4, or a pharmacologically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: November 23, 2009
    Publication date: April 1, 2010
    Inventors: Takaichi Shimozato, Takashi Kagari, Hiromi Doi
  • Patent number: 7687491
    Abstract: A compound having immunosuppressive activity with low toxicity or a pharmacological salt thereof.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: March 30, 2010
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Takahide Nishi, Tsuyoshi Nakamura, Yukiko Sekiguchi, Yumiko Mizuno, Takaichi Shimozato, Futoshi Nara
  • Publication number: 20100035842
    Abstract: A compound having a formula II(a): , wherein R1 and R2 are hydrogen lower alkyl, lower aliphatic acyl, or lower alkoxycarbonyl; R4 is C1-C4 alkyl; n is 2 or 3; X is a formula ?N-D, wherein D is hydrogen, C1-C6 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH2—, —CH(OH)— CH2— or phenylene; Z is C1-C6 alkylene; R5 is C3-C10 cycloalkyl or C6-C10 aryl; R6 and R7 are hydrogen, lower alkyl, halogeno lower alkyl, lower alkoxy or lower alkylthio; and R10 and R11 are hydrogen or lower alkyl.
    Type: Application
    Filed: July 24, 2009
    Publication date: February 11, 2010
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Takahide NISHI, Takaichi SHIMOZATO, Futoshi NARA, Shojiro MIYAZAKI
  • Publication number: 20090326038
    Abstract: A method for treating an immunology-related disease. The method involves administering to a mammal in need thereof a pharmaceutically effective amount of an amino acid compound, a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof. The compound has the following formula: , wherein R1 and R2 are each hydrogen; R3 is hydrogen; R4 is C1-C2 alkyl; n is 2; X is ?N-D, wherein D is hydrogen, C1-C4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH2 or phenylene; Z is ethylene or trimethylene; R5 is unsubstituted C3-C10 cycloalkyl, unsubstituted C3-C10 aryl, or C3-C10 cycloalkyl or C6-C10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R6 and R7 are each hydrogen.
    Type: Application
    Filed: August 12, 2009
    Publication date: December 31, 2009
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Takahide Nishi, Takaichi Shimozato, Futoshi Nara, Shojiro Miyazaki
  • Patent number: 7638551
    Abstract: A method for the prevention or treatment of an immunology-related disease, which is not rheumatoid arthritis or psoriasis, in a mammal in need thereof which involves administering to the mammal a pharmaceutically effective amount of a compound, a pharmacologically acceptable salt of the compound or a pharmacologically acceptable ester of the compound, wherein the compound is a compound having a formula (Ia): wherein R1 and R2 are each a hydrogen, R3 is hydrogen; R4 is C1-C2 alkyl; n is 2; X is ?N—D, wherein D is hydrogen C1-C4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH2 or phenylene; Z is ethylene or trimethylene; R5 is an unsubstituted C3-C10 cycloalkyl, an unsubstituted C6-C10 aryl, or a C3-C10 cycloalkyl or a C6-C10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R6 and R7 are each hydrogen.
    Type: Grant
    Filed: January 9, 2007
    Date of Patent: December 29, 2009
    Assignee: Sankyo Company, Limited
    Inventors: Takahide Nishi, Takaichi Shimozato, Futoshi Nara, Shojiro Miyazaki
  • Publication number: 20090062214
    Abstract: A compound having excellent macrophage activity inhibitory action, which is represented by the general following formula: wherein Q represents an oxygen atom, a C1-C3 alkylene group, a —O-Alk- group or a —O-Alk-O— group (in which Alk is a C1-C3 alkylene group), R1 represents a C1-C20 alkanoyl group which may be substituted, a C3-C20 alkenoyl group which may be substituted or a C3-C20 alkynoyl group which may be substituted, R2, R3 and R4, which may be the same or different, represent a hydrogen atom, a C1-C20 alkyl group which may be substituted, a C2-C20 alkenyl group which may be substituted, a C2-C20 alkynyl group which may be substituted, a C1-C20 alkanoyl group which may be substituted, a C3-C20 alkenoyl group which may be substituted or a C3-C20 alkynoyl group which may be substituted, R5 represents a hydrogen atom, a halogen atom, a hydroxyl group, a C1-C6 alkoxy group which may be substituted, a C2-C6 alkenyloxy group which may be substituted or a C2-C6 alkynyloxy group which may be substituted
    Type: Application
    Filed: January 7, 2005
    Publication date: March 5, 2009
    Inventors: Masao Shiozaki, Takaichi Shimozato
  • Publication number: 20080153882
    Abstract: A pharmaceutical composition containing 1 or more PPAR regulators and 1 or more amino alcohol compounds of the formula (I): wherein R1 and R2, each represents hydrogen or alkyl; R3 represents C1-C6 alkyl or hydroxymethyl; R4 represents hydrogen, C1-C6 alkyl, alkoxy or halogen; R5 represents substituted phenyl; X represents vinylene (CH?CH), oxygen, sulfur or methylamino; Y represents a single bond, oxygen, sulfur or carbonyl; Z represents a single bond or C1-C8 alkylene; n represents 2 or 3; or pharmacologically acceptable salts thereof. The pharmaceutical composition is used to suppress rejection of organ transplants or skin grafts and to prevent or treat autoimmune diseases.
    Type: Application
    Filed: June 23, 2006
    Publication date: June 26, 2008
    Inventors: Takahide Nishi, Takaichi Shimozato, Takashi Kagari, Hiromi Doi
  • Publication number: 20080113961
    Abstract: A compound having immunosuppressive activity with low toxicity or a pharmacological salt thereof.
    Type: Application
    Filed: October 19, 2007
    Publication date: May 15, 2008
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takahide Nishi, Tsuyoshi Nakamura, Yukiko Sekiguchi, Yumiko Mizuno, Takaichi Shimozato, Futoshi Nara
  • Publication number: 20070191468
    Abstract: A pharmaceutical composition is provided that has a low toxicity, demonstrates superior physicochemical properties and pharmacokinetics, and has superior peripheral blood lymphocyte count lowering activity. The pharmaceutical composition contains a compound having general formula (I): [Chemical Formula 1] (wherein R1 represents a methyl group or an ethyl group, R2 represents a methyl group or an ethyl group, and R3 represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.
    Type: Application
    Filed: February 23, 2005
    Publication date: August 16, 2007
    Inventors: Takahide Nishi, Toshiyasu Takemoto, Shojiro Miyazaki, Takaichi Shimozato, Futoshi Nara, Takashi Izumi
  • Publication number: 20070149597
    Abstract: A pharmaceutical composition useful as a preventive or therapeutic agent for immune-related diseases. The pharmaceutical composition includes at least HMG-COA reductase inhibitor and at least one amino alcohol compound having the following formula (I), a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof wherein R1 and R2 each represents hydrogen; R3 represents lower alkyl or hydroxymethyl; R4 represents hydrogen, alkyl, alkoxy or halogen; R5 represents hydrogen, halogeno, cyclohexyl or phenyl; X represents vinylene (CH?CH), oxygen, sulfur or methylated nitrogen; Y represents a single bond, oxygen, sulfur or carbonyl; Z represents a single bond or C1-C8 alkylene; n is 2 or 3.
    Type: Application
    Filed: January 26, 2007
    Publication date: June 28, 2007
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Takahide Nishi, Takaichi Shimozato, Takashi Kagari, Hiromi Doi
  • Publication number: 20070142335
    Abstract: A method for the prevention or treatment of an immunology-related disease, which is not rheumatoid arthritis or psoriasis, in a mammal in need thereof which involves administering to the mammal a pharmaceutically effective amount of a compound, a pharmacologically acceptable salt of the compound or a pharmacologically acceptable ester of the compound, wherein the compound is a compound having a formula (Ia): wherein R1 and R2 are each a hydrogen, R3 is hydrogen; R4 is C1-C2 alkyl; n is 2; X is ?N-D, wherein D is hydrogen C1-C4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH2 or phenylene; Z is ethylene or trimethylene; R5 is an unsubstituted C3-C10 cycloalkyl, an unsubstituted C6-C10 aryl, or a C3-C10 cycloalkyl or a C6-C10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R6 and R7 are each hydrogen.
    Type: Application
    Filed: January 9, 2007
    Publication date: June 21, 2007
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Takahide Nishi, Takaichi Shimozato, Futoshi Nara, Shojiro Miyazaki
  • Publication number: 20070105933
    Abstract: A method for the preventing a disease selected from the group consisting of rheumatoid arthritis and psoriasis in a mammal, such as a human, in need thereof, which includes administering to the mammal a pharmaceutically effective amount of a compound of formula (Ia) wherein R1 and R2 are each hydrogen; R3 is hydrogen; R4 is C1-C2 alkyl; n is 2; X is=N-D, wherein D is hydrogen, C1-C4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH2 or phenylene; Z is ethylene or trimethylene; R5 is an unsubstituted C3-C10 cycloalkyl, an unsubstituted C6-C10 aryl, or a C3-C10 cycloalkyl or C6-C10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R6 and R7 are each hydrogen.
    Type: Application
    Filed: December 11, 2006
    Publication date: May 10, 2007
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Takahide Nishi, Takaichi Shimozato, Futoshi Nara, Shojiro Miyazaki